Preserved prenatal lung growth assessed by fetal MRI in the omicron-dominated phase of the SARS-CoV-2 pandemic - Takeaways - MDSpire

Preserved prenatal lung growth assessed by fetal MRI in the omicron-dominated phase of the SARS-CoV-2 pandemic

  • By

  • Gloria Biechele

  • Vanessa Koliogiannis

  • Philippe Rennollet

  • Tobias Prester

  • Enrico Schulz

  • Thomas Kolben

  • Magdalena Jegen

  • Christoph Hübener

  • Uwe Hasbargen

  • Andreas Flemmer

  • Olaf Dietrich

  • Tanja Burkard

  • Regina Schinner

  • Julien Dinkel

  • Maximilian Muenchhoff

  • Susan Hintz

  • Maria Delius

  • Sven Mahner

  • Jens Ricke

  • Anne Hilgendorff

  • Sophia Stoecklein

  • August 30, 2024

  • 0 min

Share

  • 1

    Fetal MRI showed reduced lung volume in offspring of women with mild SARS-CoV-2 infection during the alpha phase of the pandemic.

  • 2

    The omicron variant resulted in lower disease severity and improved perinatal outcomes compared to earlier SARS-CoV-2 variants.

  • 3

    Vaccination policies included pregnant women, contributing to hybrid immunity during the omicron-dominated phase of the pandemic.

  • 4

    The study involved 24 pregnant women with mild SARS-CoV-2 infections, with most experiencing symptoms classified as mild.

  • 5

    Fetal lung volumes were assessed via MRI and compared to non-COVID controls, revealing less severe placental changes in omicron infections.

Original Source(s)

Preserved prenatal lung growth assessed by fetal MRI in the omicron-dominated phase of the SARS-CoV-2 pandemic

  • by Gloria Biechele, Vanessa Koliogiannis, Philippe Rennollet, Tobias Prester, Enrico Schulz, Thomas Kolben, Magdalena Jegen, Christoph Hübener, Uwe Hasbargen, Andreas Flemmer, Olaf Dietrich, Tanja Burkard, Regina Schinner, Julien Dinkel, Maximilian Muenchhoff, Susan Hintz, Maria Delius, Sven Mahner, Jens Ricke, Anne Hilgendorff, Sophia Stoecklein

  • August 30, 2024

Related Content

Trust in US health agencies appears to be eroding

HIV Status and COVID-19 Treatment Disparities in the US National Clinical Cohort Collaborative

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.